<h4>Context</h4>Intermediate-term glycemic control metrics fulfill a need for measures beyond hemoglobin A1C.<h4>Objective</h4>Compare glycated albumin (GA), a 14-day blood glucose measure, with other glycemic indices.<h4>Design</h4>24-week prospective study of assay performance.<h4>Setting</h4>8 US clinics.<h4>Participants</h4>Subjects with type 1 (n = 73) and type 2 diabetes (n = 77) undergoing changes to improve glycemic control (n = 98) or with stable diabetes therapy (n = 52).<h4>Interventions</h4>GA, fructosamine, and A1C measured at prespecified intervals. This evidence concerns the gene ALB and type 2 diabetes mellitus.